MedTrace Logo

PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802

NCT01672905 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2017-05-17

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

PURPOSE: This clinical trial studies prostate-specific antigen (PSA) antibody levels in samples from patients treated for prostate cancer on trial ECOG-E9802.

Conditions

Interventions

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    lead NETWORK

Principal Investigators

  • Robert S. DiPaola, MD · Rutgers Cancer Institute of New Jersey

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-07
Primary Completion
2013-01-07
Completion
2013-01-07

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01672905 on ClinicalTrials.gov